Sort
64,565 grants matching “drug discovery”
Targeting Biotin Metabolism in Mycobacterium Tuberculosis
$779,863Courtney C Aldrich · University Of Minnesota · R01 · FY2021 · AI
Targeting Biotin Metabolism in Mycobacterium Tuberculosis
$779,863Courtney C Aldrich · University Of Minnesota · R01 · FY2020 · AI
Evaluating the Impact of Non-COPD Medications on COPD Management
$779,839Katsiaryna Bykov · Brigham And Women'S Hospital · R01 · FY2025 · HL
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome
$779,817Yuan Liu · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · AI
Function and Structure Adaptations in Forebrain Development
$779,796Pat R Levitt · Children'S Hospital Of Los Angeles · R01 · FY2020 · MH
Determinants of oral anaphylaxis to food
$779,775Adam Williams · Northwestern University At Chicago · R01 · FY2025 · AI
Novel Antithrombotic Diadenosine Tetraphosphate Analogs
$779,748Ivan B Yanachkov · Glsynthesis, Inc. · R44 · FY2010 · HL
Linkage-specific ubiquitylation patterns as highly sensitive markers for neurodegenerative disease
$779,745Tauseef R. Butt · Lifesensors, Inc. · R44 · FY2019 · AG
Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae.
$779,645Joseph A Duncan · Univ Of North Carolina Chapel Hill · U01 · FY2023 · AI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site
$779,640David Eric Gerber · Ut Southwestern Medical Center · UG1 · FY2023 · CA
Small Molecule Inhibitors of Ebola Virus Polymerase Function
$779,570Christopher F Basler · Georgia State University · R01 · FY2019 · AI
Small Molecule Inhibitors of Ebola Virus Polymerase Function
$779,568Christopher F Basler · Georgia State University · R01 · FY2020 · AI
NEW CHEMICAL ENTITIES AND UNIQUE TARGETS FOR HCMV
$779,490University Of Michigan At Ann Arbor · P01 · FY2002 · AI
Preclinical assessment of GCPII inhibitors for cognition and tau pathology
$779,486Amy F.t. Arnsten · Yale University · R01 · FY2021 · AG
Drug repositioning for Alzheimer's disease via genetics, electronic health records, and human iPSC models
$779,465Bingshan Li · Vanderbilt University · R01 · FY2024 · AG
Drug repurposing for Alzheimer's disease using structural systems pharmacology.
$779,392Lei Xie · Hunter College · R01 · FY2019 · AG
Drug repurposing for Alzheimer's disease using structural systems pharmacology.
$779,392Lei Xie · Hunter College · R01 · FY2018 · AG
Drug repurposing for Alzheimer's disease using structural systems pharmacology.
$779,392Lei Xie · Hunter College · R01 · FY2021 · AG
Drug repurposing for Alzheimer's disease using structural systems pharmacology.
$779,392Lei Xie · Hunter College · R01 · FY2022 · AG
Drug repurposing for Alzheimer's disease using structural systems pharmacology.
$779,392Lei Xie · Hunter College · R01 · FY2020 · AG
Evolution and inhibition of carbapenemase in beta-lactam resistance
$779,337Yu Chen · University Of South Florida · R01 · FY2025 · AI
Drug discovery of COMT inhibitors to treat cognitive deficits in schizophrenia
$779,257James Barrow · Lieber Institute, Inc. · R01 · FY2019 · MH
Managing Atherosclerosis by Modulating HDL Function
$779,185M. Reza Ghadiri · Scripps Research Institute, The · R01 · FY2022 · HL
VGER, the Vanderbilt Genome-Electronic Records Project
$779,116Dan M Roden · Vanderbilt University Medical Center · U01 · FY2017 · HG
OTHER FUNCTIONS: PRECLINICAL MEDICATIONS DISCOVERY & ABUSE LIABILITY TESTING FOR NIDA. EXERCISE OF OPTION PERIOD N01DA-12-8904. PERIOD OF PERFORMANCE FEBRUARY 22, 2012 - FEBRUARY 21, 2017.
$778,964Louis S. Harris · Virginia Commonwealth University · N01 · FY2016 · DA